3 Oral Rehydration, Global Generic and Pharmacy Chain Stocks With a Strong Future Roadmap: FDC, Aurobindo Pharma and Medplus Health Services
- October 13, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
FDC Rs 341.40, P/E 18.05. Aurobindo Pharma Rs 1,706.90, P/E 25.46. Medplus Rs 627.60, P/E 36.06. Closing prices of 12 Oct 2026.
Quick Answer
Oral rehydration, global generic and pharmacy chain stocks with the clearest long-term roadmaps today include FDC in oral rehydration products with eye, ear and anti-infective formulations, Aurobindo Pharma in generic formulations and active ingredients for global markets and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 3.9% at FDC, 5.6% at Aurobindo Pharma and 12.6% at Medplus. P/E stands at 18.05 for FDC (industry 37.59), 25.46 for Aurobindo Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Oral rehydration, global generic and pharmacy chain stocks give investors exposure to medicines and pharmacy stores that patients and global buyers rely on. Prescription growth, export approvals and store additions decide how much of that demand turns into profit.
This list covers three oral rehydration, global generic and pharmacy chain stocks: FDC for oral rehydration products with eye, ear and anti-infective formulations, Aurobindo Pharma for generic formulations and active ingredients for global markets and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oral Rehydration, Global Generic and Pharmacy Chain Stocks?
Oral rehydration, global generic and pharmacy chain stocks are shares of companies that make medicines or sell them through pharmacy stores. Results depend on prescription growth, export approvals and store additions, so growth and margins separate the stronger names.
Oral Rehydration, Global Generic and Pharmacy Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three oral rehydration, global generic and pharmacy chain stocks as of the 12 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| FDC | 341.40 | 5,281 | 18.05 | 37.59 | 11.32% | 0.01 |
| Aurobindo Pharma | 1,706.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Medplus Health Services | 627.60 | 7,589 | 36.06 | 66.59 | 11.12% | 0.72 |
Among healthcare stocks, all three trade at a discount to their industry P/E multiples.
Why Do Oral Rehydration, Global Generic and Pharmacy Chain Stocks Have a Strong Roadmap in India?
Oral rehydration, global generic and pharmacy chain stocks have a strong roadmap in India because health spending, global demand for affordable generics and organised pharmacy growth keep lifting these businesses. Three drivers stand out.
- Everyday health: Rehydration and acute care products see repeat demand.
- Generic exports: Global buyers prefer affordable Indian medicines.
- Organised retail: Pharmacy chains gain share from small stores.
FDC: Established Brands Drive the Pipeline
FDC’s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.
Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.
Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap
Medplus’ roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.
Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.
Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.
Best Oral Rehydration, Global Generic and Pharmacy Chain Stocks in India: FDC vs Aurobindo Pharma vs Medplus on Key Financials
Among the best oral rehydration, global generic and pharmacy chain stocks in India, FDC leads on return on equity and the lowest P/E; Aurobindo Pharma leads on FY26 operating margin; Medplus leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | FDC | Aurobindo Pharma | Medplus |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 2,284.45 | 34,145.17 | 6,963.79 |
| FY26 revenue growth | 3.9% | 5.6% | 12.6% |
| FY26 net profit (Rs Cr) | 281.42 | 3,502.97 | 219.61 |
| FY26 net profit growth | 5.5% | 0.6% | 46.2% |
| FY26 operating profit margin | 20.21% | 21.61% | 9.85% |
| Q1 FY27 revenue growth (YoY) | 4.6% | 18.1% | 21.9% |
| Return on equity | 11.32% | 9.25% | 11.12% |
| P/E ratio | 18.05 | 25.46 | 36.06 |
| Debt to equity | 0.01 | 0.21 | 0.72 |
| Dividend yield | 1.54% | 0.25% | 0.00% |
| FY26 operating cash flow (Rs Cr) | 200.45 | 5,526.37 | 495.58 |
Healthcare earnings follow prescription growth, export approvals and store additions, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Oral Rehydration, Global Generic and Pharmacy Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen oral rehydration, global generic and pharmacy chain stocks and shortlist oral rehydration, global generic and pharmacy chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Oral Rehydration, Global Generic and Pharmacy Chain Stocks
- Pricing rules: Price controls and export pricing can affect margins.
- Competition: Online and offline rivals can pressure sales.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track FDC, Aurobindo Pharma and Medplus live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover rehydration products, global generics and a pharmacy retail chain. FDC leads on return on equity and the lowest P/E; Aurobindo Pharma leads on FY26 operating margin; Medplus leads on FY26 revenue growth and Q1 FY27 revenue growth.
Across oral rehydration, global generic and pharmacy chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the oral rehydration, global generic and pharmacy chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Oral Rehydration, Global Generic and Pharmacy Chain Stocks
Which are the best oral rehydration, global generic and pharmacy chain stocks in India with a strong roadmap?
Ans. FDC, Aurobindo Pharma and Medplus Health Services stand out for their roadmaps in rehydration products, global generics and a pharmacy retail chain. FY26 revenue growth was 3.9% at FDC, 5.6% at Aurobindo Pharma and 12.6% at Medplus, and return on equity ranges from 9.25% to 11.32%.
Is FDC a good stock to buy now?
Ans. FDC has a debt to equity ratio of 0.01, a return on equity of 11.32% and a P/E of 18.05 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of FDC, Aurobindo Pharma and Medplus?
Ans. The P/E ratio is 18.05 for FDC (industry 37.59), 25.46 for Aurobindo Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). All of them trade below the industry multiple.
Which of these oral rehydration, global generic and pharmacy chain stocks has the highest return on equity?
Ans. FDC has the highest return on equity at 11.32%, followed by Medplus Health Services at 11.12% and Aurobindo Pharma at 9.25%.
What are the risks of investing in oral rehydration, global generic and pharmacy chain stocks?
Ans. The main risks are pricing rules, competition and quarterly trends. Price controls and export pricing can affect margins.
How did FDC, Aurobindo Pharma and Medplus perform in Q1 FY27?
Ans. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year.
Do oral rehydration, global generic and pharmacy chain stocks pay dividends?
Ans. FDC and Aurobindo Pharma pay dividends. The dividend yield is 1.54% for FDC and 0.25% for Aurobindo Pharma, based on dividends declared for FY26.
How can I invest in oral rehydration, global generic and pharmacy chain stocks in India?
Ans. You can buy oral rehydration, global generic and pharmacy chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
